Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148418 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
A Phase 3 study of Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 382
- Enrollment target
- 20
- Study locations
NCT03148418 is a Phase 3 study of Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 382 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03148418, a Phase 3 study of Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 382 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
- University Of Chicago Medical Center - Chicago
- Ingalls Memorial Hospital - Harvey
- Illinois Cancer Care - Peoria
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) - Fort Myers
- Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie
- Florida Cancer Specialists. - St. Petersburg
- H. Lee Moffitt Cancer Center and Research Inst. - Tampa
California
- Angeles Clinic & Rsch Inst - Los Angeles
- UCLA - Los Angeles
- Kaiser Permanente - San Diego (Zion Ave) - San Marcos
Colorado
- University Of Colorado - Aurora
- Rocky Mountain Cancer Ctr - Denver (Williams) - Denver
Arizona
- HonorHealth Research Institute ? Bisgrove - Scottsdale
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2030-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148418
The ClinicalTrials.gov registry entry for NCT03148418 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03148418 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03148418 about?
NCT03148418 is a clinical study titled "A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)". This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive s...
What is the current status of trial NCT03148418?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 382 participants. The study started on 2017-09-20. Estimated completion is 2030-03-06.
What conditions does trial NCT03148418 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03148418?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03148418?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03148418 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.